Hello, Somehow, we’ve made it to the end of July. If you can believe it, that means we here in the US have been in this pandemic for five months. Is anyone keeping up with the hobbies they picked up in March? This week in healthcare news, vaccine candidates moved […]
Shares of Sorrento Therapeutics spiked as much as 244% on Friday after the company claimed an antibody it’s developing showed 100% inhibition of the COVID-19 virus in preclinical studies. The small biotechnology company said it aims to create an antibody cocktail that would act as a “protective shield” against coronavirus. […]
Researchers are looking into whether high doses of famotidine, the active ingredient in the heartburn medication Pepcid, could be used to treat critically ill patients with COVID-19, the disease caused by the novel coronavirus. The researchers are based at the Feinstein Institutes for Medical Research, the research arm of New […]
Johnson & Johnson announced Monday that it identified a lead COVID-19 vaccine candidate that could begin human trials in September and be ready for emergency authorization use in 2021. Shares of the healthcare company surged as much as 9% during regular trading. J&J will expand manufacturing capacity to produce the […]
Aimmune Therapeutics stock surged ahead of market open Monday, after the FDA announced Friday it had approved Aimmune’s peanut allergy treatment for children. It’s the first such treatment to gain approval from the FDA. Shares jumped as much as 17% Monday morning. Visit Business Insider’s homepage for more stories. The […]
Gilead announced Sunday it will pay $US5.1 billion to increase its stake in Belgian biotech company Galapagos to 22% from 12.3%. Galapagos shares rose as much as 18% in early trading Monday. The decade-long collaboration deal gives Gilead rights outside Europe to Galapagos’ drug pipeline. Watch Galapagos trade live here. […]
Swiss drug giant Novartis is developing drugs that could prevent cancer before patients get it. Jay Bradner, who heads up Novartis’s drug research and discovery, says that in a “doomsday” scenario, this may end up being the only cure for cancer. But health insurers might not want to pay for […]
The FDA on Monday approved a new cancer treatment in an unconventional way: not by tumour type, but rather by the genetic mutation the drug targets. The drug, Vitrakvi, was developed by Loxo Oncology in partnership with pharma giant Bayer. It’s only the second time the FDA has approved a […]
23andMe on Wednesday announced a partnership with pharma giant GlaxoSmithKline to develop new treatments for diseases including Parkinson’s disease, in which GSK is providing $US300 million in funding to 23andMe. 23andMe’s CEO Anne Wojicki sent an email to users on Wednesday announcing the partnership and explaining why the consumer genetics […]
Popular DNA-testing companies like Ancestry and 23andMe can – and frequently do – sell your data to drugmakers. On Wednesday, the pharmaceutical giant GlaxoSmithKline announced it was acquiring a $US300 million stake in 23andMe, making that connection much more explicit. If that new has you wondering about how your own […]
Biotech company Prothena said on Monday that its drug to treat AL Amyloidosis, a rare disease in which amyloid protein builds up in the body and disrupts organ function, failed a key trial. The drug, NEOD001, failed a phase 2 trial, and the company decided to discontinue its later-stage phase […]
NASH, short for nonalcoholic steatohepatitis, is a type of liver disease in which liver fat builds up in people. It affects an estimated 16 million Americans, but many don’t know it until it leads to more serious problems like liver failure and cirrhosis. Work’s being done to pinpoint how to […]
The FDA just turned away Alkermes’ approval submission for its new drug to treat major depressive disorder. Alkermes‘ stock was down as much as 19% on Monday morning before markets opened. Alkermes said in a news release that the FDA told the company it wouldn’t review the drug because of […]
TwoXar, a startup that uses software to discover new experimental drugs, just raised $US10 million. The series A round was led by SoftBank Ventures, with Andreessen Horowitz and OS Fund joining in. The company hopes to identify new treatments that can be tested on animals, and then ideally with human […]
Out of all the most appealing areas of the US...
Celgene turned in a brutal third-quarter...
To combat recent stock weakness, Botox-maker...
Next Page »
